InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-35.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Pauls Dietrich John, Chairman & CEO. Insider active across 1 company, notably DiaMedica Therapeutics Inc.. Cumulatively, 4 filings have been published. Split: 4 buys · 0 sell. Total volume traded: €96k. History available since 16 August 2021. The latest transaction was disclosed on 23 June 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
12,787 shares@ US$3.9147.7% of flowVoting Common Shares, no par value per shareSEC:0001235802-23-000072:0
Ideal exit: 19 Mar 2024 (T+270)
20,000 shares@ US$1.2124.4% of flowVoting Common Shares, no par value per shareSEC:0001235802-22-000121:0
Ideal exit: 13 Aug 2023 (T+270)
5,000 shares@ US$3.140.0032% mcap50.0% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000098:0
Ideal exit: 13 May 2022 (T+270)
5,000 shares@ US$3.1413.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000098
Ideal exit: 13 May 2022 (T+270)
4 of 4 declarations
About Pauls Dietrich John
John Pauls is the President and CEO of DiaMedica Therapeutics Inc., a biopharmaceutical company. In his role, he is responsible for the strategic direction of the company and the management of its operations. With experience in the biopharmaceutical sector, he plays a key role in developing new treatments and driving innovation.
